CKD273尿液肽分类器筛查2型糖尿病CKD进展的成本效果
在2型糖尿病患者中,CKD进展可能不伴尿白蛋白排泄率(UAE)变化。本研究用决策分析Markov模型比较CKD273分类器与UAE年度筛查的成本效果,发现CKD273筛查更贵但更有效,ICER为€23,903/QALY,高危患者中成本节省,低危患者不具成本效果。
要点
- CKD273筛查较UAE筛查每患者增量成本€3,053,获得0.13 QALYs。
- 全人群ICER €23,903/QALY,低于政府支付阈值。
- 高危患者中CKD273筛查为优势策略(更有效且更便宜)。
核心结论
- 在2型糖尿病患者中,CKD273分类器年度筛查较UAE年度筛查更贵但更有效,全人群具成本效果。
- 高危患者中CKD273筛查为优势策略,低危患者中不具成本效果。
研究设计与样本
- 决策分析Markov模型,从卫生系统视角估算成本和健康产出(总生存率和QALYs)。
- 在假设的2型糖尿病队列中比较CKD273分类器年度筛查与UAE年度筛查。
主要发现
- 全2型糖尿病患者中,CKD273筛查增量成本€3,053/患者,获得0.13 QALYs。
- 全人群ICER为€23,903/QALY,低于当前政府资助阈值。
- 高危患者中CKD273筛查为成本节省(dominant)。
- 低危患者中CKD273筛查ICER为€73,140/QALY,不具成本效果。
关键数值与推荐
- 高危患者定义为2型糖尿病合并至少一项危险因素(遗传风险、肥胖、高血压和/或吸烟史)。
- 低危患者定义为无上述合并危险因素。
- 全人群ICER €23,903/QALY,低危人群ICER €73,140/QALY。
临床怎么用
- 对2型糖尿病合并高危因素患者,可考虑CKD273分类器年度筛查以节省成本并提高效果。
- 低危患者中CKD273筛查不具成本效果,需谨慎选择。
局限性
- 结果为基于假设队列的模型估算,需真实世界验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate. A new urinary peptide classifier (CKD273) has exhibited greater ability to detect CKD progression, however, its cost-effectiveness remains unknown. This study evaluated the cost-effectiveness of screening for CKD progression with the CKD273 classifier, as compared to UAE, in diabetic patients. METHODS: A decision-analytic Markov model was developed to estimate costs and health outcomes [including overall survival and quality-adjusted life years (QALYs)] from a health system perspective for adopting a new annual screening strategy based on the CKD273 classifier as compared to annual UAE-based screening in a hypothetical cohort of T2DM patients. High-risk patients were defined as T2DM patients with at least one concomitant risk factor (i.e. patients with background genetic risk for developing the disease, obesity, hypertension and/or smoking history) for developing diabetic nephropathy secondary to cardiovascular disease (CVD)-related complications. Low-risk T2DM patients, were defined as those not having any of the aforementioned concomitant risk factors. RESULTS: Over the projected course of a patient's lifetime, in all T2DM patients annual screening with the CKD273 classifier was more costly, but also more effective, than annual screening with UAE. The incremental costs incurred with screening based on the CKD273 classifier were €3,053 per patient, while patients gained 0.13 QALYs. Hence, in all patients, annual screening with the CKD273 classifier was cost effective [incremental cost-effectiveness ratio (ICER) €23,903/QALY gained], notably below current government thresholds for funding such health care interventions. For patients at high risk of developing diabetic nephropathy secondary to CVD-related complications, screening based on the CKD273 classifier was cost-saving (i.e. dominant, being both more effective and less expensive than UAE-based screening). Finally, in low-risk patients, CKD273 classifier-based screening was not cost effective (ICER €73,140/QALY) given current government willingness-to-pay thresholds. CONCLUSIONS: In diabetic patients, annual CKD273 classifier-based screening is more costly but also more effective in QALYs gained as compared to UAE. From a health provider perspective, the observed benefits are greatest when such screening is implemented in patients at high risk for diabetes-associated renal or cardiovascular diseases (CVDs).
引用
- Critselis E, Vlahou A, Stel VS, et al. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrol Dial Transplant. 2018. PMID: 29106632. doi:10.1093/ndt/gfx068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。